{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:51:21Z","timestamp":1778071881547,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To systematically evaluate the effect of sacubitril\/valsartan (SV) on the prognosis of patients with acute myocardial infarction (AMI), and to provide evidence for expanding the clinical application of SV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PubMed, EMbase, Web of Science, and Cochrane Library were searched from inception to October 2023 for randomized controlled trials (RCTs) of SV in patients with AMI. The article was screened and evaluated by the Cochrane 5.1.0 bias risk assessment tool. RevMan5.3 was used for meta-analysis of the outcome indicators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Ten RCTs involving 7230 patients were included. The results showed that SV increased left ventricular eject fraction (<jats:italic toggle=\"yes\">MD<\/jats:italic>\u2005=\u20052.86, 95% CI [1.81\u20133.90], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.00001) and reduced readmission rate (<jats:italic toggle=\"yes\">RR<\/jats:italic>\u2005=\u20050.46, 95% CI [0.32\u20130.68], <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>&lt;\u20050.0001), decreased N-terminal pro-brain natriuretic peptide (<jats:italic toggle=\"yes\">MD<\/jats:italic> = \u2212477.46, 95% CI [\u2212914.96 to \u221239.96], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.03), and reduced major adverse cardiovascular and cerebrovascular event (MACCE) (<jats:italic toggle=\"yes\">RR<\/jats:italic>\u2005=\u20050.48, 95% CI [0.27\u20130.85], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.01). There was no significant difference in the rate of adverse reaction (AR) between the trial group and the control group (<jats:italic toggle=\"yes\">RR<\/jats:italic>\u2005=\u20050.88, 95% CI [0.60\u20131.30], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.52).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SV can effectively improve the prognosis of AMI, prevent complications, and there is no significant difference in safety compared with angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001332","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:00:33Z","timestamp":1706763633000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Sacubitril\/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis"],"prefix":"10.1097","volume":"35","author":[{"given":"Fang","family":"Wang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Weifang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengde","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Weifang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Care Medicine, Weifang Hospital of Traditional Chinese Medicine, Weifang, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.jacc.2022.08.797","article-title":"Risk factors for in-hospital cardiac arrest in patients with st-segment elevation myocardial infarction.","volume":"80","author":"Gong","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2012.02.028","article-title":"Prognostic value of reverse left ventricular remodeling after primary angioplasty for STEMI.","volume":"222","author":"Carrabba","year":"2012","journal-title":"Atherosclerosis"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1148\/radiol.2015142674","article-title":"Prediction of reverse remodeling at cardiac MR imaging soon after first ST-Segment-Elevation myocardial infarction: results of a large prospective registry.","volume":"278","author":"Bodi","year":"2016","journal-title":"Radiology"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jacbts.2017.08.001","article-title":"Cardioprotective effects of LCZ696 (sacubitril\/valsartan) after experimental acute myocardial infarction.","volume":"2","author":"Ishii","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","article-title":"Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits.","volume":"72","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"18","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction.","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy.","volume":"146","author":"Shah","year":"2022","journal-title":"Circulation"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MCA.0000000000000955","article-title":"Benefits of early administration of Sacubitril\/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.","volume":"32","author":"Zhang","year":"2021","journal-title":"Coron Artery Dis"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1059420","DOI":"10.3389\/fcvm.2022.1059420","article-title":"Effects of sacubitril\/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.","volume":"9","author":"Yang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/IJGM.S389216","article-title":"Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction.","volume":"16","author":"Fan","year":"2023","journal-title":"Int J Gen Med"},{"key":"R13-20250729","first-page":"7650937","article-title":"Effect of Entresto on Clinical Symptoms, Ventricular Remodeling, Rehabilitation, and Hospitalization Rate in Patients with Both Acute Myocardial Infarction and Acute Heart Failure.","volume":"2022","author":"Wang","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000527357","article-title":"The Value of Sacubitril\/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.","volume":"147","author":"Lin","year":"2022","journal-title":"Cardiology"},{"issue":"Supplement","key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0735-1097(23)01775-8","article-title":"The Role of Sacubitril\/Valsartan in post-acute myocardial infarction (RSVP-AMI TRIAL).","volume":"81","author":"Abdelnabi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.carrev.2021.06.032","article-title":"\u2018The role of sacubitril-valsartan in post-acute myocardial infarction (RSV-PAMI) trial: preliminary results\u2019.","volume":"28","author":"Abdelnabi","year":"2021","journal-title":"Cardiovasc Revasc Med"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patients with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.","volume":"32","author":"Wang","year":"2021","journal-title":"Coron Artery Dis"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JIM.0000000000000232","article-title":"Acute complications of myocardial infarction in the current era: diagnosis and management.","volume":"63","author":"Bajaj","year":"2015","journal-title":"J Investig Med"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/eurheartj\/ehv769","article-title":"The search for optimal dual antiplatelet therapy after PCI: fine-tuning of initiation and duration.","volume":"37","author":"L\u00fcscher","year":"2016","journal-title":"Eur Heart J"},{"key":"R20-20250729","first-page":"274","article-title":"Non-invasive ventilation improves hemorheology status in hypoxemic patients with acute myocardial infarction after PCI.","volume":"14","author":"Wang","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchf.2014.10.007","article-title":"Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction The SWEDEHEART Registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008.","volume":"3","author":"Desta","year":"2015","journal-title":"JACC Heart Fail"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R23-20250729","first-page":"544","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"74","author":"Collet","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis.","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"e12435","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction.","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"R27-20250729","first-page":"78","article-title":"Superiority of wall motion score index over left ventricle ejection fraction in predicting cardiovascular events after an acute myocardial infarction.","volume":"8","author":"Jurado-Rom\u00e1n","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.hrtlng.2021.07.007","article-title":"Association of N-terminal pro-brain natriuretic peptide level with adverse outcomes in patients with acute myocardial infarction: A meta-analysis.","volume":"50","author":"Shen","year":"2021","journal-title":"Heart Lung"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:02:57Z","timestamp":1753812177000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001332","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}